EVARREST Fibrinogen Human and Human Thrombin 8.6 mg/cm2; 37.5 [iU]/cm2 Patch — NDC 63713-050-24 (Billing 63713-0050-24)
This is a package of EVARREST Fibrinogen Human and Human Thrombin 8.6 mg/cm2; 37.5 [iU]/cm2 Patch from Ethicon, Inc., first listed with the FDA Mar 2013 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 63713-050-24 alone.
- Record
- FDA NDC Directory package listing · Plasma derivative
- Code segments
- 63713 labeler · 050 product · 24 package
- Package marketed since
- Mar 1, 2013
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 6371305024 4
- FDA record last changed
- Nov 1, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 074756
- GCN: 39498
- HICL (First Databank): 035080
- AHFS class code: 84:24.12.00
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 63713-0050-24 You're viewing this Main listing | 2 POUCH in 1 CARTON / 1 TRAY in 1 POUCH / 52 cm2 in 1 TRAY Inner NDC 63713-050-25 · each pouch (1 tray) | 2013-03-01 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Evarrest 8.6 mg/cm2; 37.5 [iU]/cm2this 63713-0050-24 | Ethicon, | 2 pouches | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Purple Book · refreshed Nov 5, 2026
- CMS NADAC weekly file
Availability & biosimilar status
Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.
Why the date isn’t exact: Biosimilar timing can change because patents may be challenged, settled, licensed, added or removed, and litigation can move the real date earlier or later.
🛈 What do these terms mean?
- Biologic patent
- A patent the reference product’s maker has publicly listed. A biosimilar generally can’t launch until these expire — unless they’re invalidated or resolved in a settlement.
- Reference-product exclusivity
- A flat 12 years of FDA market protection from the biologic’s first licensure (the BPCIA). No biosimilar can be licensed before it ends, regardless of patents.
- Interchangeable exclusivity
- The first interchangeable biosimilar can earn a period as the only interchangeable version (pharmacists can substitute it without the prescriber).
- Earliest biosimilar (LOE)
- The latest of all the dates above — the soonest a biosimilar can realistically reach the market. Litigation and settlements can move it earlier.
Biologics have no small-molecule “generics” — competition comes from FDA-licensed biosimilars, tracked in the FDA Purple Book.
| Code | What it grants | Expires |
|---|---|---|
| RefProduct | Reference-product exclusivity (12-year, BPCIA) — no biosimilar can be licensed before this date | Dec 5, 2024 |
Is there a biosimilar for EVARREST 2"X4" PATCH?
Why do different websites show different biosimilar dates?
Can a biosimilar launch before the last patent expires?
What does “current Purple Book estimate” mean?
What does “FDA listed” mean?
What does a patent or protection date mean here?
Where does this data come from?
- FDA Purple Book · refreshed Nov 5, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII ZIF514RVZR
A protein derived from human blood plasma. In medicines, it acts as a stabilizer and binder, helping maintain drug potency and form, and may improve how the medication disperses or dissolves in the body.
-
UNII F7LTH1E20Y
Arginine hydrochloride is an amino acid salt used as a buffer and pH adjuster in medicines. It helps maintain the correct acidity level to keep the drug stable and effective.
-
UNII M4I0D6VV5M
Calcium chloride is a salt compound that acts as a firming agent and source of calcium ions in medications. It's used in formulations to help maintain tablet structure, improve texture, or serve as a buffering agent.
-
UNII TE7660XO1C
Glycine is an amino acid used in medicines as a buffer to help stabilize pH and improve taste. It may also serve as a filler or binder to give the product proper form and consistency.
-
UNII 3OWL53L36A
A natural sugar alcohol derived from seaweed or synthesized in the lab. It's used as a filler to add bulk, a sweetener in sugar-free formulas, and a disintegrant to help tablets break apart in the stomach.
-
UNII 4550K0SC9B
Sodium acetate is a salt derived from acetic acid. It acts as a buffer to help maintain the medicine's pH stability and may serve as a preservative or solubilizer in liquid formulations.
-
UNII 451W47IQ8X
Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
-
UNII 1Q73Q2JULR
Sodium citrate is a salt derived from citric acid. It works as a buffer to maintain the medicine's pH level and may also help improve taste or act as a preservative in the formulation.
8 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Ethicon, Inc. labeler code 63713
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full FDA label FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE EVARREST ® is indicated for use with manual compression as an adjunct to hemostasis in adult and pediatric patients undergoing surgery, when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. Limitations of Use: Cannot safely or effectively be used in place of sutures or other forms of mechanical ligation in the treatment of major arterial or venous bleeding. Not for use in laparoscopic and other minimally invasive surgeries where manual compression would be difficult to achieve.
EVARREST is a fibrin sealant patch indicated for use with manual compression as an adjunct to hemostasis in adult and pediatric patients undergoing surgery, when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. ( 1 ) Limitations of Use: Cannot be used in place of sutures or other forms of mechanical ligation in the treatment of major arterial or venous bleeding. ( 1 ) Not for use in laparoscopic and other minimally invasive surgeries where manual compression would be difficult to achieve.
( 1 )
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION For topical use only. Determine the number of patches to be applied based on target bleeding site and anatomic location of the bleeding tissue to be treated. ( 2.1 ) The maximum size of EVARREST to be implanted is 6.9 cm 2 per kilogram of body weight.
Do not use more than eight 2 inch × 4 inch (5.1 cm × 10.2 cm) patches. ( 2.1 ) Keep the patch dry until use. ( 2.2 ) Place the powdery (active) side of the patch on the surface of tissue.
( 2.3 ) Apply immediate manual compression over the entire surface of the patch and maintain contact pressure for 3 minutes to control the bleeding. ( 2.3 )
2.1Dose For topical use only. Determine the number of patches to be applied based on target bleeding site and anatomic location of the bleeding tissue to be treated. The maximum size of EVARREST ® to be implanted is 6.9 cm 2 per kilogram of body weight. Do not use more than eight 2 inch × 4 inch (5.1 cm × 10.2 cm) patches.
2.2Preparation EVARREST comes ready to use in sterile packages and must be handled using sterile technique in aseptic conditions. Discard damaged packages as resterilization is not possible. To open the product, remove the foil pouch from the carton, carefully peel open the foil pouch, avoiding contact with the inside of the foil or the white sterile tray containing EVARREST.
Remove the white sterile tray from the pouch and place onto the sterile field. Hold the tray securely in the palm of the hand, ensuring that the side with the holes is facing upwards, and use the tabs on the side of the tray to remove the top of the tray with the other hand. The lower portion of the tray contains EVARREST with the active side facing downwards.
The active side is powdery in appearance. The non-active side has an embossed wave pattern. Keep EVARREST dry after opening.
The patch can remain in the sterile field to be available for use throughout the procedure. EVARREST does not stick to gloves, forceps, or surgical instruments.
2.3Application Apply topically to the bleeding site only. Using sterile scissors, carefully cut the patch to the size and shape as necessary to fit and maintain contact with the bleeding area with an overlap of approximately 0.5 to 1 inch (1 to 2 cm). Keep the powdery white-to-yellow color active side of the patch facing down while in the tray.
Remove excess blood or fluid from the site of application to improve visibility. Do not use on non-visualized surfaces. Do not use to treat bleeding from defects in large arteries or veins where the injured vascular wall requires conventional surgical repair for maintenance of vessel patency.
Apply the active side of the patch to the bleeding area. Allow full contact with the tissue or prosthetic graft. The product is activated upon contact with fluid and then adheres, conforming to tissue with continuous manual compression.
Apply a sufficient number of patches to adequately cover the entire bleeding area, with an overlap of approximately 0.5 to 1 inch (1 to 2 cm). Use the least number of patches to cover the bleeding area [see Warnings and Precautions (5.6) ] . (a) Hold dry or moist laparotomy pads or surgical gauze over EVARREST to achieve full contact with the bleeding surface.
(b) To ensure hemostasis, immediately apply continuous manual compression over the entire surface of the patch (including the area of overlap) sufficient to stem all bleeding. Ensure even pressure distribution, full tissue apposition and avoid movement of the patch over the entire bleeding area. Maintain continuous manual compression for 3 minutes.
Gently remove laparotomy pads or surgical gauze from the application site without disrupting or dislodging EVARREST or the clot. If irrigation is necessary, use care not to dislodge the patch. Inspect the patch to ensure that it is in full contact with the treated area.
If placement of the patch is unsatisfactory, remove the patch and use a new patch [see Dosage and Administration (2) ] . Removal of the patch may disrupt t… [Excerpted — this section continues on DailyMed.]
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS EVARREST ® Fibrin Sealant Patch consists of human fibrinogen and human thrombin embedded in a flexible composite patch component. The active side is white-to-yellow in color and powdery in appearance, and the non-active side has an embossed wave pattern. Each 2 inch × 4 inch (5.1 cm × 10.2 cm) absorbable patch of EVARREST contains 55.5 mg per square inch (8.6 mg per square cm) of human fibrinogen and 241.9 Units The Thrombin potency expressed in Units is determined using a clotting assay against an internal reference standard for potency that has been calibrated against the World Health Organization (WHO) Second International Standard for Thrombin, 01/580.
Therefore, a Unit used herein is equivalent to an International Unit. per square inch (37.5 Units per square cm) of human thrombin. EVARREST Fibrin Sealant Patch consists of human fibrinogen and human thrombin embedded in a flexible composite patch component. The active side is powdery, and the non-active side has an embossed wave pattern.
( 3 ) Each 2 inch × 4 inch (5.1 cm × 10.2 cm) absorbable patch contains: 55.5 mg per square inch (8.6 mg per square cm) human fibrinogen 241.9 Units per square inch (37.5 Units per square cm) human thrombin ( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS EVARREST ® is contraindicated for: Treating bleeding from large defects in visible arteries or veins where the injured vascular wall requires conventional surgical repair and maintenance of vessel patency or where there would be persistent exposure of EVARREST to blood flow and/or pressure during absorption of the product. [ Warnings and Precautions (5.1) ]. Intravascular application. This can result in life-threatening thromboembolic events. [ Warnings and Precautions (5.1) ].
Individuals known to have anaphylactic or severe systemic reaction to human blood products. [ Warnings and Precautions (5.2) ]. Do not use to treat bleeding from large defects in arteries or veins. ( 4 ) Do not apply intravascularly.
( 4 ) Do not use in individuals known to have anaphylactic or severe systemic reaction to human blood products. ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Thrombosis can occur if absorbed systemically. Apply topically to the bleeding site only. ( 5.1 ) Hypersensitivity reactions including anaphylaxis can occur.
( 5.2 ) Avoid application to contaminated areas of the body or in the presence of active infection. Infection can occur. ( 5.3 ) EVARREST contains oxidized regenerated cellulose which adheres to bleeding surfaces.
Inadvertent adhesions can occur. ( 5.4 ) Avoid use in, around, or in proximity to, foramina in bone or areas of bony confine where swelling may cause compression. ( 5.5 ) Use the least number of patches required to cover the entire bleeding area.
( 5.6 ) May carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.7 )
5.1Thrombosis Thrombosis can occur if EVARREST is absorbed systemically when placed intravascularly. Apply EVARREST topically to the bleeding site only.
5.2Hypersensitivity Reactions EVARREST can cause hypersensitivity reactions, including anaphylactic reactions. Symptoms associated with allergic anaphylactic reactions include flush, urticaria, pruritus, nausea, drop in blood pressure, tachycardia or bradycardia, dyspnea, severe hypotension and anaphylactic shock.
5.3Infection Avoid application to contaminated or infected areas of the body, or in the presence of active infection. Infection can occur from application to an infected site.
5.4Adhesions EVARREST contains oxidized regenerated cellulose which adheres to bleeding surfaces. Inadvertent adhesions can occur.
5.5Nerve or Blood Vessel Compression Nerve or blood vessel compression may occur due to swelling after EVARREST treatment. Therefore, avoid using EVARREST in, around, or in proximity to, foramina in bone or areas of bony confine where swelling may cause nerve or blood vessel compression.
5.6Migration of Dislodged Patch Material Portions of excess patch material can become dislodged and migrate to other areas of the body. Therefore, use the least number of patches possible during surgical procedures.
5.7Transmissible Infectious Agents Because the biological components of this product are made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk of transmitting viral agents has been minimized by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and removing certain viruses during the manufacturing process [see Description (11) ] .
Despite these measures, such products still potentially can transmit disease. There is also the possibility that unknown infectious agents may be present in such products. Any infection considered by a physician to possibly have been transmitted by this product should be reported by the physician or other healthcare provider to ETHICON Customer Support Center at 1-877-384-4266.
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS Adverse reactions reported during clinical trials occurred in less than 1% of all cases. These events were: abdominal abscess, anastomotic hemorrhage, blood fibrinogen increased, deep venous thrombosis, intestinal ischaemia, intra-abdominal hemorrhage, localized intra-abdominal fluid collection, operative hemorrhage, peripancreatic fluid collection, pleural effusion, post procedural hemorrhage, and pulmonary embolism. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact ETHICON Customer Support Center at 1-877-384-4266 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates of adverse reactions in clinical trials of another drug and may not reflect the rates observed in clinical practice. In adult and pediatric populations, EVARREST has been used to treat parenchymal hepatic bleeding during intra-abdominal surgery and soft tissue bleeding during retroperitoneal, intra-abdominal, pelvic, and non-cardiac thoracic surgery.
It has been further studied in the adult population for parenchymal bleeding during renal surgery and anastomotic bleeding during cardiovascular surgery. Across all clinical studies, 511 adult and pediatric patients were treated with EVARREST (456 adults; 55 pediatric) and 367 patients (347 adults; 20 pediatric) received control treatment (218 adult patients were exposed to standard of care methods; 99 to TachoSil Fibrin Sealant Patch, and 30 to SURGICEL Original. In pediatric patients, 20 patients were exposed to SURGICEL Original in the control group).
All patients treated with EVARREST were assessed for adverse reactions. In two clinical studies, assessment of adverse reactions for the Control group (standard of care treatment) was not required, therefore, of the 367 control patients, 240 patients were in studies where an assessment was required. Of the patients with assessments, 3.7% EVARREST patients (19/511) and 4.2% Control patients (10/240) experienced one or more adverse reaction.
All adverse reactions reported in clinical trial patients treated with EVARREST (511 patients), occurred at a frequency of less than 1% of patients. Adverse reactions reported as single occurrences were; abdominal abscess, intestinal ischaemia, localized intra-abdominal fluid collection, peripancreatic fluid collection, and pulmonary embolism. Additional events reported in >1 patient were; anastomotic hemorrhage (3 patients, 0.6%), blood fibrinogen increased (3 patients, 0.6%), deep vein thrombosis (2 patients, 0.4%), intra-abdominal hemorrhage (2 patients, 0.4%), operative hemorrhage (2 patients, 0.4%), pleural effusion (2 patients, 0.4%), and post procedural hemorrhage (2 patients, 0.4%).
In the Control groups, adverse reactions reported as single occurrences were blood fibrinogen increased (0.4%, standard of care treatment), intra-abdominal hemorrhage (0.4%, oxidized regenerated cellulose), pleural effusion (0.4%, standard of care treatment), and rash (0.4%, TachoSil Fibrin Sealant Patch). Additional events reported were operative hemorrhage (3 patients, 1.3%, oxidized regenerated cellulose), and anastomotic hemorrhage (3 patients, 1.3% TachoSil Fibrin Sealant Patch). A prospective, randomized, controlled single-center post-marketing safety study observing the clinical utility of EVARREST against Standard of Care (SoC) in soft tissue bleeding during intra-abdominal, retroperitoneal, pelvic and non-cardiac thoracic surgery was conducted.
SoC was manual compression (MC) with or without a topical absorbable hemostat (TAH) or any other adjunctive hemostasis technique that was deemed by the surgeon to be his/her SoC. The incidence of thromboembolic events, the incidence of post-operative bleeding events specifically related to the target bleeding site and the incidence of increased blood fibrinogen levels were assess… [Excerpted — this section continues on DailyMed.]
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS
8.1Pregnancy Risk Summary In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. There are no data with EVARREST ® use in pregnant women to inform a drug-associated risk. Animal reproduction studies have not been conducted with EVARREST.
It is not known whether EVARREST can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. EVARREST should be applied to a pregnant woman only if clearly needed.
8.2Lactation Risk Summary There is no information regarding the presence of any component of EVARREST in human milk, the effect on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EVARREST and any potential adverse effects on the breastfed infant from EVARREST or from the underlying maternal condition.
8.4Pediatric Use The safety and effectiveness of EVARREST have been established in pediatric patients. The use of EVARREST in pediatric patients was supported by evidence from one adequate and well-controlled randomized clinical study in 40 pediatric patients (20 in EVARREST, 20 in control arm using SURGICEL Original) (EVARREST mean age 4.60 years, SD 4.193; SURGICEL Original mean age 5.46 years, SD 4.778), and one open-label, single-arm clinical study of 35 pediatric patients (mean age 4.59 years SD 4.341). The randomized clinical study included pediatric patients in the following age groups to EVARREST: 6 infants (1 month up to less than 2 years), 11 children (2 years up to less than 11 years), and 3 adolescents (12 years to <17 years).
In the open-label, single-arm study, 12 infants (1 month up to less than 2 years), 18 children (2 years up to less than 11 years), and 5 adolescents (12 years to <17 years) were treated. The safety and effectiveness of EVARREST in neonates <1 month old was extrapolated from the clinical evidence from the two pediatric trials in those 1 month to <17 years of age. [see Adverse Reactions (6.1) , Clinical Pharmacology (12) , and Clinical Studies (14) ].
8.5Geriatric Use Clinical trials included 181 patients of 65 years of age or older who were treated with EVARREST. No differences in safety or efficacy were observed between the elderly and younger patients.
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. There are no data with EVARREST ® use in pregnant women to inform a drug-associated risk. Animal reproduction studies have not been conducted with EVARREST.
It is not known whether EVARREST can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. EVARREST should be applied to a pregnant woman only if clearly needed.
🧒 Pediatric Use ▾
8.4Pediatric Use The safety and effectiveness of EVARREST have been established in pediatric patients. The use of EVARREST in pediatric patients was supported by evidence from one adequate and well-controlled randomized clinical study in 40 pediatric patients (20 in EVARREST, 20 in control arm using SURGICEL Original) (EVARREST mean age 4.60 years, SD 4.193; SURGICEL Original mean age 5.46 years, SD 4.778), and one open-label, single-arm clinical study of 35 pediatric patients (mean age 4.59 years SD 4.341). The randomized clinical study included pediatric patients in the following age groups to EVARREST: 6 infants (1 month up to less than 2 years), 11 children (2 years up to less than 11 years), and 3 adolescents (12 years to <17 years).
In the open-label, single-arm study, 12 infants (1 month up to less than 2 years), 18 children (2 years up to less than 11 years), and 5 adolescents (12 years to <17 years) were treated. The safety and effectiveness of EVARREST in neonates <1 month old was extrapolated from the clinical evidence from the two pediatric trials in those 1 month to <17 years of age. [see Adverse Reactions (6.1) , Clinical Pharmacology (12) , and Clinical Studies (14) ].
🧓 Geriatric Use ▾
8.5Geriatric Use Clinical trials included 181 patients of 65 years of age or older who were treated with EVARREST. No differences in safety or efficacy were observed between the elderly and younger patients.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action The mechanism of action of EVARREST ® is based on the interaction between the biological components and the physiology of the fibrin clot formation. Upon contact with a bleeding wound surface, the biological components embedded in the patch component are hydrated, and the subsequent fibrinogen-thrombin reaction initiates the last step in the cascade of biochemical reactions - conversion of fibrinogen into fibrin monomers that further polymerize to form the fibrin clot. Hemostasis is achieved when the formed fibrin clot integrates with the patch component and adheres to the wound surface thus also providing a physical barrier to bleeding.
12.6Immunogenicity Immunogenicity was evaluated in soft tissue clinical studies by testing blood samples collected for antibodies to human thrombin and fibrinogen. Three patients out of 145 (~2%) in the group treated with EVARREST showed an increase in the titer of anti-thrombin antibodies after treatment. Two patients out of 145 (~1%) in the group treated with EVARREST showed a transient increase in fibrinogen antibody titers, with titer levels back at background levels 8 to 10 weeks after treatment.
None of the patients in any treatment group had a significant change in antibody titer to thrombin or fibrinogen. The general antibody level in the treated population was not affected by treatment with EVARREST and resembled the normal levels in healthy patients. Use in patients who have been previously exposed to EVARREST has not been studied.
🧬 Mechanism of Action ▾
12.1Mechanism of Action The mechanism of action of EVARREST ® is based on the interaction between the biological components and the physiology of the fibrin clot formation. Upon contact with a bleeding wound surface, the biological components embedded in the patch component are hydrated, and the subsequent fibrinogen-thrombin reaction initiates the last step in the cascade of biochemical reactions - conversion of fibrinogen into fibrin monomers that further polymerize to form the fibrin clot. Hemostasis is achieved when the formed fibrin clot integrates with the patch component and adheres to the wound surface thus also providing a physical barrier to bleeding.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING EVARREST ® is packaged in a polyester tray and lid assembly within an outer pouch composed of polyester laminated aluminum foil with an inner heat seal coating. The tray and lid assembly maintains product integrity during storage and transport. The aluminum foil pouch serves as a barrier to moisture and microbial contamination to maintain product sterility.
Each aluminum foil pouch is contained in a labeled cardboard package. Each individual package contains two 2 inch × 4 inch (5.1 cm × 10.2 cm) EVARREST patches (NDC 63713-050-25 per patch and NDC 63713-050-24 per package). Use EVARREST before the expiration date indicated on the carton.
Store unopened packages of EVARREST at 2°C to 25°C (36°F to 77°F). EVARREST does not require refrigeration. Do not freeze.
Do not use if package is opened or damaged. Once opened, keep EVARREST dry to avoid activation of the biological components prior to use.
📦 Storage and Handling ▾
Use EVARREST before the expiration date indicated on the carton. Store unopened packages of EVARREST at 2°C to 25°C (36°F to 77°F). EVARREST does not require refrigeration. Do not freeze. Do not use if package is opened or damaged. Once opened, keep EVARREST dry to avoid activation of the biological components prior to use.
📋 Description ▾
11 DESCRIPTION EVARREST ® Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component. The active side is white-to-yellow in color and powdery in appearance; the non-active side has an embossed wave pattern. The patch component of EVARREST consists of an oxidized regenerated cellulose (ORC) layer underlying a layer of polyglactin 910 (PG910) non-woven fibers.
The PG910 layer contains the embedded biological components. The patch component provides a large surface area for the biological components and imparts inherent mechanical integrity to the product. The flexibility of EVARREST accommodates the physiological movements of tissues and organs.
Each 2 inch × 4 inch (5.1 cm × 10.2 cm) EVARREST patch contains 55.5 mg per square inch (8.6 mg per square cm) of human fibrinogen and 241.9 Units per square inch (37.5 Units per square cm) of human thrombin. Additional inactive ingredients are: arginine hydrochloride, calcium chloride, glycine, human albumin, mannitol, sodium acetate, sodium chloride, and sodium citrate. EVARREST does not contain any preservative.
EVARREST is sterilized by electron-beam irradiation after completion of inner and outer packaging resulting in a sterile product in a sterile inner package. Viral Clearance The biological components of EVARREST (human fibrinogen and human thrombin) are manufactured from pooled human plasma collected in FDA-licensed facilities in the United States. Human plasma is tested by FDA-licensed Nucleic Acid Tests (NAT) for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus-1 (HIV-1).
NAT testing for hepatitis A virus (HAV) and parvovirus B19 is also performed. In addition, human plasma is tested for the presence of hepatitis B surface antigen (HBsAg) and antibodies to hepatitis C virus (anti-HCV) and human immunodeficiency viruses types 1 and 2 (anti-HIV1/2). The manufacturing procedure for human fibrinogen and human thrombin include processing steps designed to reduce the risk of viral transmission.
In particular, the virus clearance steps in the manufacture of human fibrinogen include solvent/detergent (S/D) treatment and pasteurization. The virus clearance steps in the manufacture of human thrombin include S/D treatment and nanofiltration. The virus clearance capacity of these procedures has been validated using viruses with a range of physico-chemical characteristics.
These in vitro validation studies were conducted using samples from manufacturing intermediates spiked with virus suspensions of known titers followed by further processing under conditions equivalent to those in the respective manufacturing steps. The results of virus clearance validation studies are summarized in Table 1 and Table 2. Table 1.
Virus Reduction Factors for Human Fibrinogen Reduction Factor (log 10 ) of virus tested HIV-1: Human Immunodeficiency Virus Type 1 BVDV: Bovine Viral Diarrhea Virus PRV: Pseudorabies Virus Enveloped Viruses EMCV: Encephalomyocarditis Virus HAV: Hepatitis A Virus CPV: Canine Parvovirus Non-Enveloped Viruses Manufacturing Step HIV-1 BVDV PRV EMCV HAV CPV SD Treatment > 4.42 > 4.39 >
3.96 Not Tested Not Tested
0.0Pasteurization > 4.39 > 5.46 6.04 3.69 > 5.78
1.33Cumulative Virus Reduction Factor > 8.81 > 9.85 > 10.00 3.69 > 5.78
1.33Table 2. Virus Reduction Factors for Human Thrombin Reduction Factor (log 10 ) of virus tested HIV-1: Human Immunodeficiency Virus Type 1 SBV: Sindbis Virus BVDV: Bovine Viral Diarrhea Virus PRV: Pseudorabies Virus Enveloped Viruses EMCV: Encephalomyocarditis Virus HAV: Hepatitis A Virus CPV: Canine Parvovirus Non-Enveloped Viruses Manufacturing Step HIV-1 SBV BVDV PRV EMCV HAV CPV SD Treatment > 5.82 > 5.31 > 4.74 >
4.25 Not Tested Not Tested
0.0Nanofiltration > 4.36 >
5.32Not Tested > 5.47 6.37 6.95
5.85Cumulative Virus Reduction Factor > 10.18 > 10.63 > 4.74 > 9.72 6.… [Excerpted — this section continues on DailyMed.]
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Advise patients to consult their physician if they experience chest pain, shortness of breath, difficulty speaking or swallowing, leg tenderness or swelling, or other symptoms of thromboembolism. Inform patients that EVARREST ® may carry a risk of transmitting infectious agents, e.g., viruses such as hepatitis A and parvovirus B19 and theoretically the CJD agent. Instruct patients to consult their physician if symptoms of B19 virus infection (fever, drowsiness, and chills, followed two weeks later by a rash and joint pain) or hepatitis A (several days to weeks of poor appetite, fatigue and low-grade fever followed by nausea, vomiting and abdominal pain, dark urine, yellowed complexion) appear.
Distributed by: Ethicon, Inc. 1000 Route 202 Raritan, NJ 08869 USA Manufactured by: Omrix Biopharmaceuticals Ltd. 14 Einstein Street Weizmann Science Park Nes-Ziona, Israel US License No.
1879 © 2026 Ethicon, Inc. Art. No.
80XZ24Z3SX
🔬 Clinical Studies ▾
14 CLINICAL STUDIES
14.1Abdominal, pelvic, retroperitoneal, and non-cardiac thoracic Surgery A prospective, randomized controlled trial including 141 patients (median age: 62 years; range 26 to 89 years) was performed to compare the safety and hemostatic effectiveness of EVARREST ® with that of oxidized regenerated cellulose (ORC), an absorbable hemostat, when used as an adjunct to control bleeding after primary methods to achieve hemostasis (e.g., suture, cautery, ligature) proved ineffective or impractical during open abdominal, pelvic, retroperitoneal, and non-cardiac thoracic surgery.
A total of 90 patients were randomized in a 2:1 ratio (60 treated with EVARREST, 30 treated with ORC). An additional 51 patients were enrolled and treated with EVARREST during a subsequent non-randomized phase. Of the total 141 enrolled patients, 63.1% were male; 80.1% were White/Caucasian; 18.4% were Black; 0.7% were Asian; and 0.7% were Hispanic/Latino.
Median body mass index was 27 kg/m 2 (range: 17 to 53 kg/m 2 ). Demographic characteristics were balanced across treatment groups. EVARREST demonstrated a statistically significant difference compared with ORC, 98.3% versus 53.3% (p < 0.0001) in the proportion of patients achieving hemostatic success at 4 minutes after identification of the target bleeding site and randomization, with no re-bleeding requiring treatment during a subsequent 6-minute observation period and sustained hemostasis until fascial closure at the end of the surgery (Table 3).
Table 3. Patients Achieving Hemostasis at 4 Minutes from Identification of the Target Bleeding Site and Randomization, with no Re-bleeding until Fascial Closure at the End of the Surgery EVARREST ORC p-value Treatment Difference 95% Confidence Interval 59/60 (98.3%) 16/30 (53.3%) <0.0001 45.0% 27.9%, 62.5% Efficacy data for the 51 non-randomized patients treated with EVARREST were supportive of the above findings, with 50/51 patients (98.0%) achieving hemostatic success at 4 minutes after randomization. No re-bleeding requiring treatment occurred during a subsequent 6-minute observation period.
14.2Liver Surgery Two prospective, randomized controlled trials including a total of 206 patients were performed to compare the safety and hemostatic effectiveness of EVARREST with that of Standard of Care (defined as manual compression with or without a topical absorbable hemostat) when used as an adjunct to control bleeding after primary methods to achieve hemostasis (e.g., suture, cautery, ligature) proved ineffective or impractical during liver surgery. The first study included 104 patients (median age: 65 years; range 31 to 82 years): 58.7% of the patients were male; 95.2% were White/Caucasian; 1.9% were Asian; and 1% were Black.
Median body mass index was 27kg/m 2 (range: 15 to 43 kg/m 2 ). Demographic characteristics were balanced across treatment groups. A total of 84 patients were randomized in a 1:1 ratio (40 randomized to EVARREST, 44 to Standard of Care).
An additional 20 patients were enrolled and treated with EVARREST during a non-randomized phase. One patient should have been randomized to EVARREST but was treated with Standard of Care. This patient was analyzed in the EVARREST group for the Intent to Treat Set.
EVARREST demonstrated a statistically significant difference compared with Standard of Care (82.5% versus 29.5%; p < 0.0001) in the proportion of patients achieving hemostatic success at 4 minutes after identification of the target bleeding site and randomization, with no re-bleeding requiring treatment any time prior to initiation of wound closure (Table 4). The treatment difference between EVARREST and Standard of Care was greater in patients with bleeding from abnormal hepatic tissue (e.g., cirrhotic or steatotic) than in patients with normal tissue bleeding (65.2% versus 48.8%, respectively).
Table 4. Patients Achieving Hemostasis at 4 Minutes from Identification of the Target Bleeding Site and Randomization, with no Re-bleeding… [Excerpted — this section continues on DailyMed.]
🧪 Nonclinical Toxicology ▾
13 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals to evaluate the carcinogenic potential of EVARREST ® or studies to determine the effects of EVARREST on genotoxicity or fertility have not been performed. An assessment of the carcinogenic potential of EVARREST was completed to demonstrate minimal carcinogenic risk from product use.
13.2Animal Toxicology and Pharmacology The biological components of EVARREST are degraded by fibrinolysis and phagocytosis, similarly to endogenous fibrin. As resorption progresses, increased fibrinolytic activity is induced by plasmin, and decomposition of fibrin to fibrin degradation products is initiated. In swine and rodent models, topically applied EVARREST was absorbed at approximately 8 weeks after application with less than 10% of the initial material remaining, which further degraded exponentially over time.
In a rodent repeat-dosing model study, EVARREST was subcutaneously applied on Day 0 at twenty times the clinical dose at multiple surgical sites, or on Day 0 and 14 at ten times the clinical dose within multiple surgical sites. There was evidence of resorption at the site or sites of implantation after both single and repeated applications of EVARREST at study termination 90 days later. Repeat use of EVARREST in a rodent model was not associated with any increased local or systemic toxicological effects when used in multiple sites within the same procedure or when used in two procedures conducted 2-weeks apart at separate sites.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals to evaluate the carcinogenic potential of EVARREST ® or studies to determine the effects of EVARREST on genotoxicity or fertility have not been performed. An assessment of the carcinogenic potential of EVARREST was completed to demonstrate minimal carcinogenic risk from product use.
📄 Recent Major Changes ▾
Indications and Usage ( 1 ) 10/2026 Dosage and Administration, Dose ( 2.1 ) 10/2026
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL - 1 Patch Tray Label NDC 63713-050-25 FIBRIN SEALANT PATCH EVARREST ® Contents: 1 Absorbable Fibrin Sealant Patch Human Fibrinogen: 55.5 mg/in 2 (8.6 mg/cm 2 ) Human Thrombin: 241.9 Units/in 2 (37.5 Units/cm 2 ) Oxidized Regenerated Cellulose, Polyglactin 910 Batch No: Exp Date: Serial No: FPO 2D BARCODE 14mm x 14mm Manufactured by: Omrix Biopharmaceuticals Ltd. 14 Einstein Street Weizmann Science Park Nes-Ziona, Israel Made in Israel Distributed by: Ethicon, Inc. 1000 Route 202 Raritan, NJ 08869 USA U.S.
License No. 1879 R X only STERILE R Art. No.: 59XZ24Z3S3 REF EVT5024 2 x 4 inch inch (5.1cm x 10.2cm) Store at 2°C-25°C (36°F-77°F).
Do not use if package is opened or damaged. Do not resterilize. Topical use only Single use only Active side is powdery; non-active side has an embossed wave pattern.
PRINCIPAL DISPLAY PANEL - 1 Patch Tray Label
PRINCIPAL DISPLAY PANEL - 2 Patch Pouch Carton NDC 63713-050-24 FIBRIN SEALANT PATCH EVARREST ® Contents: 2 Absorbable Fibrin Sealant Patches Human Fibrinogen: 55.5 mg/in 2 (8.6 mg/cm 2 ) Human Thrombin: 241.9 Units/in 2 (37.5 Units/cm 2 ) Oxidized Regenerated Cellulose, Polyglactin 910 For dosage and inactive ingredients, see Prescribing Information No U.S. standard of potency Contains no preservative R X only Topical use only Single use only 2 x 4 inch inch (5.1cm x 10.2cm) 2 UNITS Read the instructions before use.
Store at 2°C-25°C (36°F-77°F). Do not freeze. Do not use if package is opened or damaged.
Do not resterilize. Active side is powdery; non-active side has an embossed wave pattern. STERILE R REF EVT5024 PRINCIPAL DISPLAY PANEL - 2 Patch Pouch Carton
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |